What are the recommended dosing guidelines for Vraylar (cariprazine) for adults with schizophrenia, bipolar I manic or mixed episodes, bipolar depression, and for elderly patients or those with hepatic impairment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Vraylar (Cariprazine) Dosing Guidelines

For adults with schizophrenia, start Vraylar at 1.5 mg once daily, with a target range of 1.5-6 mg daily; for bipolar mania, start at 1.5 mg and increase to 3 mg on Day 2, targeting 3-6 mg daily; for bipolar depression, start at 1.5 mg daily with a maximum of 3 mg daily (increase only after Day 15). 1

Administration Basics

  • Take once daily, with or without food 1
  • Critical timing consideration: Due to cariprazine's extremely long half-life (1-3 weeks for active metabolites), dose changes take several weeks to fully manifest in plasma levels 1
  • Monitor patients for adverse reactions and treatment response for several weeks after starting and after each dose adjustment 1

Schizophrenia Dosing

Adults

  • Starting dose: 1.5 mg once daily
  • Day 2: May increase to 3 mg
  • Target range: 1.5-6 mg once daily
  • Maximum: 6 mg daily
  • Dose adjustments: Can be made in 1.5 mg or 3 mg increments based on response and tolerability 1

Adolescents (13-17 years)

  • Starting dose: 0.5 mg once daily
  • Day 3: Increase to 1.5 mg
  • Day 5: May increase to 3 mg
  • Day 8: May increase to 4.5 mg
  • Target range: 1.5-4.5 mg once daily
  • Maximum: 4.5 mg daily 1

Bipolar I Disorder - Manic or Mixed Episodes

Adults

  • Starting dose: 1.5 mg once daily
  • Day 2: Increase to 3 mg (mandatory increase)
  • Target range: 3-6 mg once daily
  • Maximum: 6 mg daily
  • Dose adjustments: Can be made in 1.5 mg or 3 mg increments 1

Pediatric Patients (10-17 years)

  • Starting dose: 0.5 mg once daily
  • Day 3: Increase to 1.5 mg
  • Day 5: Increase to 3 mg
  • Day 8: May increase to 4.5 mg
  • Target dose: 3 mg or 4.5 mg once daily
  • Maximum: 4.5 mg daily 1

Bipolar I Disorder - Depressive Episodes (Adults Only)

  • Starting dose: 1.5 mg once daily
  • Day 15: May increase to 3 mg if needed
  • Maximum: 3 mg daily
  • Do not increase before Day 15 1

Major Depressive Disorder - Adjunctive Therapy (Adults Only)

  • Starting dose: 1.5 mg once daily
  • Day 15: May increase to 3 mg if needed
  • Maximum: 3 mg daily
  • Critical warning: Titration at intervals less than 14 days results in higher incidence of adverse reactions 1

Special Populations and Drug Interactions

With Strong CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin)

When starting Vraylar while on inhibitor:

  • Schizophrenia/Bipolar Mania/Bipolar Depression/MDD: Start at 0.5 mg daily; may increase to 0.75 mg if needed 1

When adding inhibitor to stable Vraylar dose:

  • If on 1.5-3 mg: Reduce to 0.5 mg daily
  • If on 4.5-6 mg: Reduce to 0.75 mg daily 1

With Moderate CYP3A4 Inhibitors (e.g., diltiazem, erythromycin)

When starting Vraylar while on inhibitor:

  • Schizophrenia: Start at 0.75 mg daily; may increase to 1.5 mg if needed
  • Bipolar Mania/Bipolar Depression/MDD: Start at 0.75 mg daily 1

When adding inhibitor to stable Vraylar dose:

  • If on 1.5-3 mg: Reduce to 0.75 mg daily
  • If on 4.5-6 mg: Reduce to 1.5 mg daily 1

With CYP3A4 Inducers

Concomitant use is NOT recommended - has not been evaluated and should be avoided 1

Pediatric Patients with CYP3A4 Inhibitors

Initiating Vraylar is NOT recommended in pediatric patients taking strong or moderate CYP3A4 inhibitors 1

Hepatic or Renal Impairment

Severe hepatic or renal disease: Vraylar should not be given 2

Key Clinical Considerations

Dosing Above Maximum Recommendations

  • Doses above 6 mg daily in schizophrenia and bipolar mania do not provide increased effectiveness sufficient to outweigh dose-related adverse reactions 1
  • This is a critical point: higher doses = more side effects without additional benefit

Most Common Adverse Effects (≥5% and twice placebo rate)

  • Schizophrenia: Extrapyramidal symptoms, akathisia 1
  • Bipolar mania: Extrapyramidal symptoms, akathisia, dyspepsia, vomiting, somnolence, restlessness 1
  • Bipolar depression: Nausea, akathisia, restlessness, extrapyramidal symptoms 1
  • MDD adjunctive: Akathisia, restlessness, fatigue, constipation, nausea, insomnia, increased appetite, dizziness, extrapyramidal symptoms 1

Metabolic Profile

Favorable metabolic profile: No significant weight gain or metabolic concerns reported; does not increase prolactin or prolong QT interval 3, 4

Contraception Requirement

Female patients of childbearing age must use effective contraception due to potential fetal harm 5

Black Box Warnings

  • Increased mortality in elderly patients with dementia-related psychosis - NOT approved for this use 1
  • Suicidal thoughts and behaviors in pediatric and young adult patients when used for depression - close monitoring required 1

References

2
Research

Cariprazine for Schizophrenia and Bipolar Disorder.

Innovations in clinical neuroscience, 2016

Related Questions

What is the recommended dosing regimen for cariprazine (Vraylar) in adult patients with schizophrenia, bipolar I mania, or bipolar I depression, including dose adjustments for patients aged 65 years or older, hepatic impairment, and renal impairment?
How does Vraylar (cariprazine) work in bipolar disorder?
Can I start this bipolar I patient with a recent lithium overdose and dangerous impulsivity on Vraylar (cariprazine) 1.5 mg for three days then increase to 3 mg instead of Depakote (valproate) because Depakote requires laboratory monitoring for acute mania?
What are the benefits of cariprazine (an atypical antipsychotic) for treating schizophrenia and bipolar I disorder?
In a 38-year-old female with major depressive disorder, generalized anxiety disorder, post-traumatic stress disorder, and a history of marijuana use who is taking cariprazine (Vraylar) 3 mg daily, clonazepam 1 mg as needed, and vilazodone 40 mg daily, what specific questions should I ask during the initial evaluation to assess for attention-deficit/hyperactivity disorder?
Can Ganaton (itopride) 50 mg three times daily cause dementia or drowsiness in an elderly patient?
What is the typical dose increase required for CYP2D6‑dependent opioids in an intermediate metabolizer?
What are examples of pre‑hepatic, hepatic, and post‑hepatic (obstructive) jaundice?
What is the next step in managing a patient with chronic insomnia who is already taking lemborexant (Dayvigo) 10 mg, has normal laboratory results, and has an MRI and polysomnography ordered but continues to have inadequate sleep?
What is the appropriate dosing and monitoring strategy for Strattera (atomoxetine) in an adult with ADHD when combined with Prozac (fluoxetine) for anxiety?
Is eosinophilic esophagitis genetic?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.